Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.

Philip D Home Lawrence BlondeSanjay KalraLi-Nong JiPatricia GuyotClaire Brulle-WohlhueterErin MurrayRoshan ShahToby SayreAlka Shaunik

Published in: Diabetes, obesity & metabolism (2020)

iGlarLixi showed similar or improved efficacy and safety versus other intensification choices from BI included in this study, providing a clinically relevant treatment option in people with type 2 diabetes not well controlled on BI.

Keyphrases

type diabetes
glycemic control
systematic review
meta analyses
randomized controlled trial
metabolic syndrome
adipose tissue
insulin resistance
weight loss
replacement therapy